Quick Answer
CUMBERLAND PHARMACEUTICALS INC reported Research And Development Expense of $5.57 million for the year ending 2025.
- CUMBERLAND PHARMACEUTICALS INC showed an increase of +15.6% in Research And Development Expense from 2024 to 2025.
- This data is from CUMBERLAND PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $1.03 million | Q3 2010: $1.14 million | Q1 2011: $1.01 million | Q2 2011: $1.03 million | Q3 2011: $1.23 million | Q1 2012: $1.40 million | Q2 2012: $1.55 million | Q3 2012: $1.70 million | Q1 2013: $1.45 million | Q2 2013: $1.39 million | Q3 2013: $1.44 million | Q1 2014: $826.4 thousand | Q2 2014: $861.2 thousand | Q3 2014: $934.8 thousand | Q1 2015: $1.86 million | Q2 2015: $828.1 thousand | Q3 2015: $757.4 thousand | Q1 2016: $706.5 thousand | Q2 2016: $678.8 thousand | Q3 2016: $644.7 thousand | Q1 2017: $898.4 thousand | Q2 2017: $1.08 million | Q3 2017: $943.2 thousand | Q1 2018: $1.87 million | Q2 2018: $1.45 million | Q3 2018: $1.31 million | Q1 2019: $1.40 million | Q2 2019: $1.72 million | Q3 2019: $1.67 million | Q1 2020: $1.72 million | Q2 2020: $1.42 million | Q3 2020: $1.23 million | Q1 2021: $1.26 million | Q2 2021: $1.36 million | Q3 2021: $1.45 million | Q1 2022: $1.75 million | Q2 2022: $1.82 million | Q3 2022: $1.71 million | Q1 2023: $1.50 million | Q2 2023: $1.15 million | Q3 2023: $1.92 million | Q1 2024: $1.16 million | Q2 2024: $1.06 million | Q3 2024: $1.31 million | Q1 2025: $1.30 million | Q2 2025: $1.47 million | Q3 2025: $1.25 million.
- Over the full 17 years of available data (2009 to 2025), CUMBERLAND PHARMACEUTICALS INC's Research And Development Expense has grown by 11.5%.
- Historical annual values: Fiscal year 2025: $5.57 million | Fiscal year 2024: $4.82 million | Fiscal year 2023: $5.83 million | Fiscal year 2022: $6.69 million | Fiscal year 2021: $5.68 million | Fiscal year 2020: $5.77 million | Fiscal year 2019: $6.87 million | Fiscal year 2018: $7.58 million | Fiscal year 2017: $4.28 million | Fiscal year 2016: $3.19 million | Fiscal year 2015: $3.85 million | Fiscal year 2014: $3.39 million | Fiscal year 2013: $5.62 million | Fiscal year 2012: $5.10 million | Fiscal year 2011: $5.03 million | Fiscal year 2010: $4.33 million | Fiscal year 2009: $4.99 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: